Assuming that systemic inflammation causes fatigue and autonomic dysfunctioning in MS patients, anti-inflammatory approaches such as IL-1β antagonists might reduce vagus nerve signaling and may, consequently, result in a reduction of fatigue and autonomic abnormalities (9). This evidence concerns the gene IL1B and myeloid sarcoma.